KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Gross Margin (2020 - 2026)

Moderna (MRNA) has disclosed Gross Margin for 7 consecutive years, with 145.5% as the latest value for Q1 2026.

  • For Q1 2026, Gross Margin fell 16217.0% year-over-year to 145.5%; the TTM value through Mar 2026 reached 22.11%, down 3104.0%, while the annual FY2025 figure was 55.35%, 59.0% up from the prior year.
  • Gross Margin hit 145.5% in Q1 2026 for Moderna, down from 33.33% in the prior quarter.
  • Across five years, Gross Margin topped out at 92.13% in Q4 2022 and bottomed at 145.5% in Q1 2026.
  • Average Gross Margin over 5 years is 28.03%, with a median of 42.51% recorded in 2024.
  • Year-over-year, Gross Margin crashed -18342bps in 2023 and then skyrocketed 14716bps in 2024.
  • Moderna's Gross Margin stood at 92.13% in 2022, then decreased by -27bps to 66.95% in 2023, then plummeted by -65bps to 23.5% in 2024, then skyrocketed by 42bps to 33.33% in 2025, then plummeted by -537bps to 145.5% in 2026.
  • According to Business Quant data, Gross Margin over the past three periods came in at 145.5%, 33.33%, and 79.63% for Q1 2026, Q4 2025, and Q3 2025 respectively.